| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YRTPH.2013.08.017 |
| P698 | PubMed publication ID | 24012707 |
| P2093 | author name string | Diann Blanset | |
| Boris Gorovits | |||
| Kelly M Flagella | |||
| Pauline L Martin | |||
| Stephane Thibault | |||
| Carmel M Lynch | |||
| Garvin Warner | |||
| Kimberly Kramer-Stickland | |||
| Paul A Andrews | |||
| Stanley A Roberts | |||
| P2860 | cites work | Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study | Q33388853 |
| P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients | Q33472987 | ||
| Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. | Q34093272 | ||
| Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75 | Q34122802 | ||
| Maturing antibody-drug conjugate pipeline hits 30. | Q34341887 | ||
| Arming antibodies: prospects and challenges for immunoconjugates | Q34449555 | ||
| A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma | Q34764827 | ||
| Drug metabolites in safety testing | Q34851293 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. | Q35004254 | ||
| Antibody targeted drugs as cancer therapeutics | Q36373103 | ||
| Technology insight: cytotoxic drug immunoconjugates for cancer therapy | Q36773469 | ||
| Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products | Q37085122 | ||
| Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products | Q37321197 | ||
| CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates | Q37402888 | ||
| Potent antibody drug conjugates for cancer therapy | Q37469585 | ||
| Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals | Q37492455 | ||
| Alternative strategies for toxicity testing of species-specific biopharmaceuticals | Q37527451 | ||
| An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies | Q37559465 | ||
| Carcinogenicity assessments of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations | Q37753534 | ||
| Investigational antibody-drug conjugates for hematological malignancies | Q37818256 | ||
| Challenges in developing bioanalytical assays for characterization of antibody-drug conjugates | Q37854644 | ||
| The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. | Q37986126 | ||
| Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. | Q39408093 | ||
| In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen | Q39507940 | ||
| An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours | Q39565827 | ||
| An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma | Q39606303 | ||
| Use of tissue cross-reactivity studies in the development of antibody-based biopharmaceuticals: history, experience, methodology, and future directions | Q39647460 | ||
| Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates | Q39778685 | ||
| Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma | Q39840659 | ||
| The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo | Q39840677 | ||
| Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models | Q40118406 | ||
| Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys | Q40395390 | ||
| Placental transfer of drugs administered to the mother | Q40530290 | ||
| Human placental Fc receptors and the transmission of antibodies from mother to fetus | Q41720397 | ||
| Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics | Q43751494 | ||
| Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice | Q44666449 | ||
| Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies | Q44957871 | ||
| PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine | Q45006316 | ||
| Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection | Q45164252 | ||
| Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. | Q46013182 | ||
| Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models | Q46407253 | ||
| Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper | Q46522736 | ||
| Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats | Q46547092 | ||
| DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma. | Q51061692 | ||
| Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. | Q55035623 | ||
| The placental transfer of IgG in the cynomolgus monkey | Q71075512 | ||
| Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products | Q80336069 | ||
| Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia | Q80401322 | ||
| The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma | Q84560547 | ||
| Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers | Q86176716 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 382-391 | |
| P577 | publication date | 2013-09-05 | |
| P1433 | published in | Regulatory Toxicology and Pharmacology | Q2138805 |
| P1476 | title | Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology | |
| P478 | volume | 67 |
| Q38347756 | An FDA oncology analysis of antibody-drug conjugates |
| Q92040902 | An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates |
| Q38537261 | An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates |
| Q35967917 | Antibody Drug Conjugates: Nonclinical Safety Considerations |
| Q38239854 | Antibody-drug conjugates: an emerging modality for the treatment of cancer |
| Q26830923 | Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies |
| Q101216241 | Considerations for setting occupational exposure limits for novel pharmaceutical modalities |
| Q38665164 | Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. |
| Q38386705 | Emerging formats for next-generation antibody drug conjugates |
| Q38838739 | Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates |
| Q46902769 | New challenges and opportunities in nonclinical safety testing of biologics |
| Q38289992 | New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics |
| Q38208275 | Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases |
Search more.